Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.
Onakpoya IJ, Heneghan CJ, Aronson JK. · 2016
Read Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. by Onakpoya IJ, Heneghan CJ, Aronson JK. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4740994.txt.
Introduction
Onakpoya, Heneghan, and Aronson systematically gather every medicinal product withdrawn from the market over suspected adverse reactions, a removal history never before mapped in full. They find 462 products withdrawn between 1953 and 2013, most often because of liver toxicity.
The evidence behind most withdrawals is thin: anecdotal reports underpin 72 percent of cases. Only 43 products, about nine percent, were withdrawn worldwide, while 39 percent disappeared in a single country, and withdrawals were least likely in Africa. The median gap between the first reported reaction and withdrawal was six years. It did not shrink over time, which the authors read as a case for better coordination between regulators.
Catalog record
| CREATOR | Onakpoya IJ, Heneghan CJ, Aronson JK. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature By Igho J Onakpoya, Carl J Heneghan, Jeffrey K Aronson Published in: BMC Medicine DOI: 10.1186/s12916-016-0553-2 ABSTRACT Abstract Background There have been no studies of the patterns of post-marketing withdrawals of medicinal products to which adverse reactions have been attributed. We identified medicinal products that were withdrawn because of adverse drug reactions, examined the evidence to support such withdrawals, and explored the pattern of withdrawals across countries. Methods We searched PubMed, Google Scholar, the WHO’s database of drugs, the websites of drug regulatory authorities, and textbooks. We included medicinal products withdrawn between 1950 and 2014 and assessed the levels of evidence used in making withdrawal decisions using the criteria of the Oxford Centre for Evidence Based Medicine. Results We identified 462 medicinal products that were withdrawn from the market between 1953 and 2013, the most common reason being hepatotoxicity. The supporting evidence in 72 % of cases consisted of anecdotal reports. Only 43 (9.34 %) drugs were withdrawn worldwide and 179 (39 %) were withdrawn in one country only. Withdrawal was significantly less likely in Africa than in other continents (Europe, the Americas, Asia, and Australasia and Oceania). The median interval between the first reported adverse reaction and the year of first withdrawal was 6 years (IQR, 1–15) and the interval did not consistently shorten over time. Conclusion There are discrepancies in the patterns of withdrawal of medicinal products from the market when adverse reactions are suspected, and withdrawals are inconsistent across countries. Greater co-ordination among drug regulatory authorities and increased transparency in reporting suspected adverse drug reactions would help improve current decision-making processes. Electronic supplementary material The online version of this article (doi:10.1186/s12916-016-0553-2) contains supplementary material, which is available to authorized users. Keywords: Adverse drug reaction, Drug withdrawal, Systematic review, Voluntary recall BACKGROUND Drug regulatory authorities award marketing authorizations that license pharmaceutical companies to market medicinal products when there is sufficient evidence that the product has a favourable benefit-to-harm balance [1]. If a new adverse drug reaction is suspected after approval, several courses of action can be taken by the regulator and/or manufacturer, including adding a new product label with specific warnings [2], adding a new contraindication [3], issuing a Direct Healthcare Professional Communication [4], allowing patients to decide whether they will take the drug [5], and in the most serious cases, withdrawal or revocation of the licence [6]. Post-approval withdrawal of medicinal products because of adverse drug reactions can be triggered by evidence obtained from various sources – anecdotal reports, observational studies, clinical trials, systematic reviews, or animal data. The removal of previously approved products from the market can result in loss of confidence in medicines by the public, loss of effective compounds (i.e. effective for treating the specific indication, but for which the benefit-to-harm balance was considered unfavourable), and loss of revenue for drug manufacturers. When there is no concrete evidence linking drug use with a suspected adverse reaction, such withdrawals can be contentious. We have previously reported inconsistencies in the pattern of withdrawals of 95 medicines to which deaths were attributed [7]. To date, there has been no comprehensive and systematic review of medicinal products that have been withdrawn because of adverse drug reactions in general. In addition, there is a paucity of data about the evidence on which such withdrawal decisions are based. Furthermore, the pattern of post-approval withdrawals across geographical regions worldwide has never been examined. Therefore, we performed a systematic review to identify medicinal products that have been withdrawn after approval because of any kinds of adverse drug reactions; to assess the types of evidence on which the withdrawal decisions were based; to identify the types of attributed adverse drug reactions responsible; to examine the patterns of withdrawal across geographical regions; to examine the intervals between launch dates and (1) the times of the first reports of adverse reactions and (2) the first dates of withdrawal; and to examine the intervals between the first reports of adverse drug reactions and the first withdrawals. METHODS Search strategy We searched for medicinal products withdrawn from the market because of adverse drug reactions between 1950 and December 2014 from the following sources: - the World Health Organization’s (WHO’s) database of Consolidated List of Products whose consumption and/or sale have been banned, withdrawn, severely restricted, or not approved by governments (Issues 6, 8, 12, and 14, and the updated version of issue 14) - the WHO’s Drug Information (Volumes 1–28) - the WHO’s Pharmaceuticals Newsletter (1997–2014) - Meyler’s Side Effects of Drugs: The International Encyclopaedia of Adverse Drug Reactions and Interactions, volumes 1–8 and editions 9–15, and the Side Effects of Drugs Annuals 1–36 - Stephens’ Detection of New Adverse Drug Reactions, 5th edition [8] - the Pharmaceutical Manufacturing Encyclopedia, 3rd edition [9] - The Merck Index, 15th Edition [10] - the website of the UK Medicines and Healthcare products Regulatory Agency - the website of the US Food and Drug Administration (FDA) - the database of withdrawn drugs of the European Medicines Agency - Health Canada Drug Product Database - the website of the Indian Central Drugs Standard Control Organization - the website of the Australian Therapeutic Goods Administration - the website of the Nigeria National Agency for Food and Drug Administration and Control - the website of the Ghana Food and Drugs Authority - the website of the South Africa Medicines Control Council - PubMed - Medline - Google Scholar Please see Additional file 1: Web 1 for full list of drug regulatory websites assessed. For each medicinal product withdrawn, we then searched PubMed, Medline, and Google Scholar for the first reported adverse drug reaction. Search terms used included “drug withdrawal”, “fatal*”, “death(s)”, “side effect”, “adverse effect”, “adverse reaction”, “adverse event”, “poison”, “toxicity”, “voluntary recall”, “suspension”, “prohibition”, “banned”, “remov*”, “revoke*”, “discontinued” (a Medline search strategy is included as a Additional file 2: Web 2). If we could not find information for a medicinal product using its chemical name for searches, we used the trade name or code name. We also searched the references of retrieved full texts for any earlier dates of reports of suspected adverse reactions. If an article had evidence of an earlier reported date, that date was chosen as the first adverse reaction date. If a drug was withdrawn because of two or more adverse reactions, we used the first reported date of any such reactions. To determine the accuracy of launch dates, we compared the information on the WHO database of Consolidated List of Products with the information in the Merck index, the Pharmaceutical Manufacturing Manual, and a newly developed database for withdrawn and discontinued products [11]. To determine the dates of first withdrawal and countries of withdrawal, we cross-checked WHO data with the database for withdrawn products; if the information was not found in that database, we compared the dates with the results of searches in PubMed and Google Scholar. Inclusion/exclusion criteria We define a medicinal product as “Any substance or combination of substances which may be used in, or administered to, human beings, either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic